The vector of switchable chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing K4 epitope linked to 4-1BB (CD137) and CD3ζ signaling domains. By using E4 epitope-tagged anti-CD19 antibody Fab, the interaction of E4/K4 will lead to the functioning of CAR-modified T cells. And the vector product was designed for the treatment of chronic lymphocytic leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MOREAngiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORETRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MOREThe latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE